Skip to content

Collaborations

Our collaborators are more than simply partners in drug discovery and development. They are thought leaders and teammates who work with us to solve global health threats.

EBANGA™

Ridgeback would like to acknowledge and thank our collaborators on the EBANGA™ (ansuvimab-zykl, mAb114) development program:

  • Biomedical Advanced Research and Development Authority (BARDA)
  • U.S. Department of Health and Human Services (HHS)
  • National Institute for Allergy & Infectious Diseases (NIAID)
  • National Institutes of Health (NIH)
  • Office of the Assistant Secretary for Preparedness and Response (ASPR)
  • The Vaccine Research Center
  • Institut National de Recherche Biomédicale de Kinshasa, République Démocratique du Congo
  • The Vaccine Clinical Materials Program (VCMP); Frederick National Laboratory for Cancer Research; sponsored by the National Cancer Institute (NCI);
  • World Health Organization (WHO)
  • The Alliance for International Medical Action (ALIMA)
  • Médecins Sans Frontières (MSF)
  • International Medical Corps (IMC)
  • Samaritan's Purse

Molnupiravir

Ridgeback would like to acknowledge and thank our collaborators on the molnupiravir (EIDD-2801) development program:

  • Emory University
  • DRIVE
  • Merck & Co
  • AGILE network